PURPOSE: To investigate multi-slice spiral CT (MSCT) imaging with breast cancer chemotherapy and the correlation between MSCT and breast cancer-specific gene 1 (BCSG1). METHODS: 86 patients with breast cancer were enrolled from January 2016 to May 2017. All of them were treated with neoadjuvant chemotherapy, and underwent MSCT scan before and after treatment to evaluate the efficacy of chemotherapy. The expression of BCSG1 in tumor tissue was detected by immunohistochemistry and the correlation between CT results and BCSG1 was analyzed. RESULTS: MSCT evaluation of the efficacy of chemotherapy in breast cancer patients was consistent with pathological evaluation (p<0.05). MSCT in patients after chemotherapy was significantly better than before chemotherapy (p<0.05). CT examination showed that tumor diameter and lymph node size were significantly reduced after chemotherapy (p<0.05). The positive rates of BCSG1 in patients with different TNM stages after chemotherapy were significantly decreased (p<0.05) and the CT perfusion value of BCSG1 in the low expression group was significantly higher than in the high expression group (p<0.05). CONCLUSIONS: MSCT can accurately evaluate the effect of chemotherapy in breast cancer. The results of MSCT were closely related to the expression of BCSG1, which may provide a reference for predicting the effect of chemotherapy in breast cancer which could have important clinical significance.
PURPOSE: To investigate multi-slice spiral CT (MSCT) imaging with breast cancer chemotherapy and the correlation between MSCT and breast cancer-specific gene 1 (BCSG1). METHODS: 86 patients with breast cancer were enrolled from January 2016 to May 2017. All of them were treated with neoadjuvant chemotherapy, and underwent MSCT scan before and after treatment to evaluate the efficacy of chemotherapy. The expression of BCSG1 in tumor tissue was detected by immunohistochemistry and the correlation between CT results and BCSG1 was analyzed. RESULTS: MSCT evaluation of the efficacy of chemotherapy in breast cancerpatients was consistent with pathological evaluation (p<0.05). MSCT in patients after chemotherapy was significantly better than before chemotherapy (p<0.05). CT examination showed that tumor diameter and lymph node size were significantly reduced after chemotherapy (p<0.05). The positive rates of BCSG1 in patients with different TNM stages after chemotherapy were significantly decreased (p<0.05) and the CT perfusion value of BCSG1 in the low expression group was significantly higher than in the high expression group (p<0.05). CONCLUSIONS: MSCT can accurately evaluate the effect of chemotherapy in breast cancer. The results of MSCT were closely related to the expression of BCSG1, which may provide a reference for predicting the effect of chemotherapy in breast cancer which could have important clinical significance.